Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Canopy Growth Corp (CGC) vs Centene Corp (CNC) Price & Performance

Canopy Growth CorpTrade
Centene CorpTrade

Price performance (Past 24H)

Key statistics

Canopy Growth Corp vs Centene Corp — how do they compare? Canopy Growth Corp trades at $0.97 (market cap $398.46M), while Centene Corp trades at $66.8 (market cap $33.93B). The key difference: Centene Corp is far larger — about 85.2× Canopy Growth Corp's market cap, and Centene Corp is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.

CGCCNC
Market Cap
$398.46M$33.93B
Sector
HealthHealth
52-Week High
$1.92$68.72
52-Week Low
$0.86$25.21
Enterprise Value
$337.90M$26.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Canopy Growth Corp

Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.

The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.

Centene Corp

Centene Corporation (CNC) trades at $68.29, up 1.4% with strong technical momentum and bullish moving average signals. The stock shows impressive 66% YTD gains, supported by recent contract renewals and margin recovery initiatives. Despite negative 2025 net income of -$6.67B, valuation metrics remain attractive with P/E of 8.06 and P/S of 0.17. Analyst consensus is strongly bullish with 61% buy ratings and $66.07 price target.

Centene presents a compelling value opportunity with low valuation multiples and strong operational cash flow of $5.09B. Key risks include ongoing margin pressure and Medicaid contract dependency. The company's AI-driven cost controls and recent Illinois Medicaid renewal provide catalysts for earnings recovery, though healthcare regulatory changes remain a concern for long-term stability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Canopy Growth Corp

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

Read more on CGC

About Centene Corp

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Read more on CNC